共 28 条
[1]
Gilling-Smith C(1997)Evidence for a primary abnormality of thecal cell steroidogenesis on the polycystic ovary syndrome Clinical Endocrinology 47 93-undefined
[2]
Story H(1993)Therapeutic use of gonadotropin-releasing hormone agonists in polycystic ovary syndrome Ann. NY Acad. Sci. 687 242-undefined
[3]
Rogers V(1997)Resistance of gonadotropin releasing hormone drive to sex steroid-induced suppression in hyperandrogenic anovulation J. Clin. Endocrinol. Metab. 82 4179-undefined
[4]
Franks S(1998)Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone J. Clin. Endocrinol. Metab. 83 582-undefined
[5]
Markussis V(1995)Metabolic effects of oral contraceptives in women with polycystic ovary syndrome J. Clin. Endocrinol. Metab. 80 3327-undefined
[6]
Goni MH(1996)Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous oral contraceptives or a gonadotropin-releasing hormone agonist Fertil. Steril. 66 54-undefined
[7]
Tolis G(1988)Gonadotropin-releasing hormone (GnRH) analog suppression render polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH J. Clin. Encrinol. Metab. 66 327-undefined
[8]
Daniels TL(undefined)undefined undefined undefined undefined-undefined
[9]
Berga SL(undefined)undefined undefined undefined undefined-undefined
[10]
Pastor CL(undefined)undefined undefined undefined undefined-undefined